糖尿病视网膜病变围手术期的抗VEGF研究

目的：对比研究玻璃体腔注射抗VEGF(血管内皮生长因子)药物治疗增殖性糖尿病视网膜病变(proliferative diabetic retinopathy，PDR)的临床疗效。

方法：选取我院2010-01/2015-01收治的PDR患者84例84眼，将患者随机分为A组、B组、C组，各为28例28眼。A组直接行玻璃体切除术； B组在玻璃体切除术前于玻璃体腔注射雷珠单抗； C组在玻璃体切除术前于玻璃体腔注射康柏西普。观察三组手术时间、并发症和术后6mo最佳矫正视力。

结果：治疗后，B组、C组术中及术后并发症的发生率以及手术时间显著低于A组。三组患者术后6mo最佳矫正视力比较，A组术前、术后视力组内比较差异均有统计学意义(P<0.05)，三组在治疗后视力改善有效率方面比较，无统计学差异(P>0.05)。

结论：玻璃体切除术前注射雷珠单抗和康柏西普能有效缩短手术时间，减少术中及术后并发症，并能显著提高患者最佳矫正视力。

Study of anti-vascular endothelial growth factor medicine for proliferative diabetic retinopathy at perioperative period

AIM:To compare clinical effects of intravitreal injection of anti-vascular endothelial growth factor(VEGF)medicine for proliferative diabetic retinopathy(PDR).

METHODS: Eighty-four patients with PDR(84 eyes)in our hospital in January 2010 to January 2015 were selected, and were randomly divided into three groups(A, B, C, 28 eyes of 28 cases ). The patients in group A underwent vitrectomy, those in group B received intravitreal injection of ranibizumab before vitrectomy; and those in group C got intravitreal injection of conbercept before vitrectomy. Operative time, complications, and postoperative best-corrected visual acuity at 6mo of the three groups were compared.

RESULTS: After treatment, the incidence of intraoperative and postoperative complications and the operation time of group B and group C were lower than those of group A. Compared best corrected visual acuity at preoperative and postoperative 6mo, and among three groups, there were no statistically significance difference(P<0.05). There were no statistical differences compared visual acuity improvement among three groups(P>0.05).

CONCLUSION: Intravitreal injection of ranibizumab and conbercept before vitrectomy can decrease the operation time and intraoperative bleeding, reduce the incidence of intraoperative and postoperative complications and improve BCVA of patients in the treatment of PDR.